Form 8-K Akoya Biosciences, Inc. For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Morgan Stanley Downgrades Akoya Biosciences Inc (AKYA) to Equalweight
August 6, 2024 12:06 PM EDTMorgan Stanley analyst Tejas Savant downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Overweight to Equalweight with a price target of $3.00 (from $4.00).
The analyst comments "Guide lowered again despite in-line qtr as placements rebound falls short of expectations on weak capital... More
BTIG Downgrades Akoya Biosciences Inc (AKYA) to Neutral
August 6, 2024 6:02 AM EDTBTIG analyst Mark Massaro downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Buy to Neutral.
The analyst comments "AKYA announced its third workforce reduction in 13 months, and lowered its 2024 revenue guidance in back-to-back quarters. Investor concerns have ranged from constrained budgets in the... More
